Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)
Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)

Otsuka Holdings Co.,Ltd.

2026-10-02 Otsuka Holdings Co.,Ltd. “A joint research and development project on next-generation cancer immunotherapy utilizing quantum computing technology, involving NEC, Taiho Pharmaceutical, the Cancer Institute, AIST, and Waseda University, has been selected for a NEDO demonstration project.”

by

2026-10-02 Otsuka Holdings Co.,Ltd. “A joint research and development project on next-generation cancer … 続きを読む

2026-10-01 Otsuka Holdings Co.,Ltd. “Taiho Pharmaceutical and Taiho Oncology have published the results of the Phase III AZTOUND trial of an oral azacitidine-cedazuridine combination drug for myelodysplastic syndrome or chronic myelomonocytic leukemia.”

by

2026-10-01 Otsuka Holdings Co.,Ltd. “Taiho Pharmaceutical and Taiho Oncology have published the results … 続きを読む

2026-09-22 Otsuka Holdings Co.,Ltd. “Positive results from a Phase 3 trial of urefnersen for amyotrophic lateral sclerosis (ALS) caused by FUS mutations – a steady step forward towards realizing gene-targeted therapy for FUS-ALS patients.”

by

2026-09-22 Otsuka Holdings Co.,Ltd. “Positive results from a Phase 3 trial of urefnersen for amyotrophic … 続きを読む

Contact